Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Clinical trial NCT07750704 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07750704
Sponsor: Guangdong Association of Clinical Trials
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ALK Positive Non-small Cell Lung Cancer

Start date: 2026-09-01
Primary completion: 2029-09-01
Enrollment: 153

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.